Background Despite the life-threatening presentation of multisystem inflammatory syndrome in children (MIS-C), the overall prognosis is favourable in centres with access to appropriate supportive care. In this study, we investigate the short-term outcomes in children with MIS-C in Cape Town, South Africa.
Methods This prospective observational cohort study included children <13 years who fulfilled the WHO case definition of MIS-C and were admitted to Tygerberg Hospital in Cape Town, South Africa between 1 June 2020 and 31 October 2021. Clinical features were recorded at baseline and at follow-up at the 6-week cardiology and 3-month rheumatology-immunology clinics, respectively.
Findings Fifty-three children with a median age of 7.4 years (IQR 4.2–9.9) were included. There was a slight male predominance (30/53; 56.6%) and the majority was of mixed ancestry (28/53; 52.83%) or black African ancestry (24/53; 45.3%). Fourteen children (14/53; 26.4%) had comorbid disease. The median length of hospital stay was 8 days (IQR 6–10). All children had an echocardiogram performed at baseline of which 39 were abnormal (39/53; 73.6%). All children were discharged alive. The median days from discharge to cardiology follow-up was 39 days (IQR 33.5–41.5) and for rheumatology-immunology clinic was 70.5 days (IQR 59.5–85.0). Eleven children (11/41; 26.8%) had a persistently abnormal echocardiogram at cardiology follow-up. Systemic inflammation and organ dysfunction resolved in most.
Interpretation Although the short-term outcomes of MIS-C in our cohort were generally good, the cardiac morbidity needs further characterisation and follow-up.
- child health
Data availability statement
Data may be obtained from a third party and are not publicly available.
This article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
WHAT IS ALREADY KNOWN ON THIS TOPIC
Despite the life-threatening presentation of multisystem inflammatory syndrome in children (MIS-C), the overall prognosis is favourable in high-income countries.
WHAT THIS STUDY ADDS
Our study adds to the very limited data of cardiovascular outcomes of children with MIS-C in Africa.
Outcomes were overall good with no deaths reported.
There were persistent abnormal echocardiograms at follow-up, suggesting that selected children will need longer follow-up to assess effect on their cardiovascular health.
Follow-up was challenging with a large proportion of children being lost despite the clinical need to see them and strategies to retain them in care.
HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY
Further research on the mid-term and long-term outcomes of MIS-C in Africa are needed to further characterise morbidity in children from Africa and to inform targeted interventions.
Multisystem inflammatory syndrome in children (MIS-C) is temporally associated with SARS-CoV-2 infection. The syndrome is characterised by fever, mucocutaneous features, hypotension, gastrointestinal symptoms and features of myocardial inflammation.1–3 MIS-C was first reported in Europe in March 2020.4–7 The first case in Cape Town, South Africa was noted in early May 2020.8
Forty to 80% of children with MIS-C required intensive care admission for haemodynamic instability.6 9 In a cohort from Lagos, Nigeria, only 10.7% (3/28) of patients were admitted to intensive care with no deaths reported.10 A systematic review of 16 case series including 655 children with MIS-C reported a mortality rate of 1.7%.11 Mortality appears to be higher in older children and those with comorbid diseases.12 In a recent report from KwaZulu Natal, South Africa, the mortality was reported much higher at 20.6%, similar to the 20% mortality in Pakistan.13 14 The mortality rate was 11.2% in a multicentre cohort including 135 children from India.15
There are no randomised data on the management of children with MIS-C but large observational studies found clinical benefit in giving both intravenous immunoglobulin (IVIG) and glucocorticoids as compared with IVIG alone.16–18 The Best Available Treatment Study consortium evaluated the use of IVIG, glucocorticoid or combination therapy in a propensity-weighted cohort study including 2101 children from 39 countries.19 They concluded that glucocorticoids appears to be a safe alternative to IVIG or combined therapy.19
The available information on long-term outcomes from North America and Europe suggests good cardiac prognosis, with systolic dysfunction recovering in the convalescent phase and most children making a full clinical recovery at 6-month follow-up.20 21 Children with cardiac dysfunction showed recovery of ventricular function and resolution of coronary artery aneurysms.22 23
We previously reported that the clinical presentation and early outcomes of South African children with MIS-C managed at Tygerberg Hospital (TBH) and Red Cross War Memorial Children’s Hospital in Cape Town are similar to European and North American children and adolescents.8 9 24 However, there are limited data on postdischarge outcomes of children with MIS-C from Africa. We aimed to evaluate the outcomes of children with MIS-C managed at TBH up to 3 months after diagnosis and beyond as indicated clinically.
Study design and population
This single-centre prospective observational study of children and adolescents <13 years diagnosed with MIS-C at TBH between 1 June 2020 and 31 October 2021 describes the clinical progress from diagnosis until approximately 3 months after diagnosis. Where children with abnormal echocardiograms were followed beyond 3 months, those data are reported up to 6 months after diagnosis.
Locally, all children and adolescents diagnosed with MIS-C are managed with supportive care, IVIG and/or intravenous or oral steroids and low-dose aspirin. All children have echocardiography on admission and follow-up. The coronary artery diameter Z-score derived from the Paediatric Heart Network Z-score system, and left ventricular ejection fraction (LVEF) measured qualitatively and quantitatively and calculated using the M-mode method are recorded.25 26 All children and adolescents are given dates for review approximately at 6 weeks after diagnosis at cardiology and at rheumatology-immunology clinic within 6 weeks to 3 months after diagnosis. The evaluation at follow-up includes a detailed clinical assessment, repeat echocardiogram and repeating inflammatory markers, COVID-19 serum antibody, renal function, liver enzymes and other investigations as indicated.
Data sources and definitions
Children and adolescents <13 years who met the WHO case definition of MIS-C were enrolled. We excluded children and adolescents in whom another plausible diagnosis was apparent; we also excluded children with typical and atypical Kawasaki disease with negative SARS COVID-2 PCR and antibody tests. Routine access to SARS-CoV-2 antibody testing against the nucleocapsid protein only became available in August 2020. Cases with MIS-C prior to August 2020 that were SARS-CoV-2 PCR negative were included if the full case definition was met and there was a positive history of exposure to a likely source case. None of these children and adolescents was vaccinated against COVID-19. South Africa only approved the use of two doses of the Pfizer-BioNTech COVID-19 vaccines for those aged 12–17 years in October 2021.27
Demographic data and clinical characteristics were reported at admission and follow-up. Care interventions including the need for intensive care intervention, IVIG and steroids were documented.
The laboratory parameters included white blood cell count, absolute lymphocyte count, absolute neutrophil count, haemoglobin, platelets, C reactive protein, ferritin, pro-brain natriuretic peptide (pro-BNP) and troponin T.
All data including echocardiograms and blood tests were performed as needed for routine care. All echocardiograms were performed by or reviewed by a paediatric cardiologist. We classified coronary artery Z-scores as follows: normal <2, dilation 2 to <2.5, aneurysm ≥2.5. Left ventricular (LV) systolic dysfunction was defined as an LVEF<55% and graded as mild (LVEF 45%–54%), moderate (LVEF 35%–44%) or severe (LVEF <35%) as previously described.15
The WHO weight-for-age Z-scores were calculated for children younger than the age of 5 years and the WHO body mass index Z-score for children over the age of 5 years using the AntrhoCalc application V.2.1.
Basic demographic data, clinical features on presentation, management and echocardiogram findings at baseline and follow-up was described using standard summary statistics. Continuous variables are summarised as mean, SD or median and IQRs where appropriate. Comparative data were analysed using IBM SPSS Statistics, V.27. Fisher’s exact test and χ2 test were used for dichotomous variables and Mann-Whitney U test for non-parametric continuous variables.
We identified 64 children and adolescents <13 years with suspected MIS-C between 1 June 2020 and 31 October 2021; we excluded 11 cases that did not meet the case definition (figure 1). The median age of the 53 patients was 7.4 years (IQR 4.3–9.9) and 30/53 (56.6%) were male (table 1). Symptoms on presentation, findings on initial clinical examination, hospital course and management are summarised in table 1.
The median length of hospital stay was 8 days (IQR 6–8). Twenty-four (45,3%) patients required intensive care admission, 22 (41.5%) patients required inotropic support and 7 (13.2%) intubation and ventilation. The majority received both IVIG and methylprednisolone (56.6%) with 18 patients (34%) receiving IVIG only.
At baseline, 39 of the 53 children (73.6%) had an abnormal echocardiogram report (table 2). The majority (29, 54,7%) had mitral or tricuspid regurgitation at baseline, 8 of the 15 patients with coronary abnormalities had brightness of the artery and although 19 (29,3%) had abnormalities of LV function only, 10 of the patients had moderate or severe dysfunction.
In the acute phase, all patients had elevated markers of systemic inflammation. The majority had lymphopenia, anaemia, renal impairment, hyponatraemia and elevated cardiac enzymes on admission. In the convalescent phase, C reactive protein and ferritin remained raised in 33 of 45 (73.3%) of children and 28/28 (100%) of children, respectively (online supplemental table 1).
By 28 February 2022, follow-up data for at least one cardiology outpatient review was available for 41/53 (77%) cases and 30/53 (56.6%) cases had at least one rheumatology follow-up (figure 1). The median days from discharge to cardiology follow-up was 39 days (IQR 33.5–41.5) and for rheumatology-immunology clinic was 70.5 days (IQR 59.5–85.0).
Thirty-three patients (33/41, 80.5%) had an initial repeat echocardiogram within 6 weeks, four patients (4/41, 9.8%) within 3 months and the remaining four (4/41, 9.8%) patients within 6 months. Eleven (11/41, 26.8%) patients had persistent abnormal findings on echocardiography at follow-up (table 3). In eight children, the persistent abnormality was due to an endocardial dysfunction manifesting as mitral or tricuspid regurgitation. Three patients had abnormalities that persisted at 6-month follow-up (patients 2, 3 and 4, table 3). Patients 2 and 3 had moderate and mild LV dysfunction, respectively and patient 4 had a dilated coronary artery (Z-score=2). We found that the median age of children with abnormal echocardiogram at follow-up was higher compared with children with normal echocardiogram at follow-up (p=0.04) and similarly children treated with both methylprednisolone and IVIG frequently had abnormal echocardiogram at follow-up compared with children with methylprednisolone or IVIG alone (p=0.02) (table 4).
Four patients (4/30, 13.3%) had ongoing clinical concerns. The first patient had an intermittent urticarial rash, dermatology diagnosed papular urticarial pustulosis, association with SARS-CoV-2 infection could not be excluded. On subsequent follow-up, the rash had resolved. The second patient had mild conjunctival injection unrelated to MIS-C. The third patient was diagnosed with myasthenia gravis shortly after admission that was temporally associated with SARS-CoV-2. She was treated with pyridostigmine and methotrexate. Nine months after initial diagnosis, she had normal function and muscle strength and all medication was successfully stopped. The fourth patient complained of headache, ankle pain and stiff legs. She had no objective clinical signs or inflammatory markers suggestive of chronic arthritis or impaired mobility. Her symptoms resolved completely at 8-month follow-up.
Follow-up laboratory parameters are summarised in online supplemental table 1. Of the 32 patients that had repeat SARS-CoV-2 antibody test at follow-up, 40.6% (13/32) remained seropositive. All patients were discharged alive from hospital.
This study adds to expanding data on the outcomes of African children with MIS-C. As in the cohort from Nigeria10 and Kenya,28 overall outcomes were good, and no children required a biologic agent. It is, however, in contrast with data recently published from KwaZulu Natal, South Africa,13 Pakistan14 and Egypt,29 where the mortality was reported to be very high (20.6%, 20% and 33.3%, respectively). Critical shortage of intensive care beds is reported from Nigeria and KwaZulu Natal. In KwaZulu Natal, limited intensive care space and delay in access to specialised care may have contributed to the high mortality. In addition, African children may have more aggressive inflammation.13 We note that children from both the cohorts from Egypt and KwaZulu Natal had a median age <5 years. It is not clear whether young age contributed to the higher mortality.
Online supplemental table 2 compares the clinical features and outcomes in children from four African countries. Detailed information on echocardiographic findings at baseline and follow-up is only provided in the Nigerian cohort and our study. Of interest, in the Kenyan cohort with only 25% (5/20) of patients receiving immune-modulation the outcomes were good with no deaths reported, compared with the higher 33.3% mortality in the Egyptian cohort where all patients received immune-modulation. The differences in mortality rates are poorly understood and this requires further analysis.
In a 6-month follow-up review of 50 children with MIS-C in New York, all had favourable cardiac outcomes with normalisation of LV systolic function, recovery of coronary abnormalities and no inflammation or scarring on cardiac MRI.20 In a systematic review, most children are reported to have complete recovery of LV dysfunction and coronary artery abnormalities at hospital discharge.11 Of concern are the 11 children with varying degrees of echocardiographic changes at their first follow-up postdischarge. Three cases showed a reduction in ejection fraction, 1 case with persistent coronary artery dilatation and 3 of the 11 cases with abnormalities persisting throughout the 6-month follow-up phase. This contrasts the Nigerian cohort which demonstrated normalisation of cardiovascular manifestations by 6 months in all.13
A group that may need further characterisation is the seven children that had persistent mild mitral or tricuspid regurgitation at cardiac follow-up. The significance of this remains unclear and it is difficult to attribute the regurgitation to something specific. Ventricular strain method was not performed on our patient population. This might have shown that these children had myocardial dysfunction even if it was not evident on M mode. Sirico et al evaluated the early and mid-term cardiac outcomes of 32 children with MIS-C by performing standard and speckle-tracking echocardiography, and cardiac magnetic resonance imaging (CMR).30 They demonstrated subclinical myocardial dysfunction still detectable at 6 months. Thirteen per cent showed persistent LV global longitudinal strain and on CMR 33.4% had persistence of late gadolinium enhancement.30 It is difficult to speculate what the cause of cardiac regurgitation is in our cohort as we did not have capacity to perform cardiac MRI to investigate for inflammation.
The median age of those with an abnormal echocardiogram at follow-up was higher than those with a normal echocardiogram. Although other cohorts also report older children having more severe disease, we should note that we did not include any children >13 years. Children who received both methylprednisolone and IVIG were also more likely to have an abnormal echocardiogram at follow-up. This may be a proxy for disease severity that we were unable to demonstrate. However, in our study we did not find an association between cardiac outcomes at follow-up and children who required PICU admission or inotropic support or those with elevated pro-BNP or troponin T, but numbers were small, and this requires further investigation.
A major concern in our study is the poor follow-up rate of children possibly related to socio-economic factors. Only 77% of children presented to cardiology clinic at 6 weeks and 57% to the rheumatology-immunology clinic by 3 months. Children in high-income country (HIC) cohorts had serial echocardiograms and rigorous multidisciplinary follow-up and clinical review. This is not always feasible in a resource-limited setting such as South Africa. It is especially concerning that 5.7% (3/53) of children in our cohort had ongoing cardiac abnormalities at 6 months in the context of 22.6% (12/53) not presenting for cardiac follow-up at all.
Emerging data indicate that children and adolescents from African countries experience higher COVID-19-related morbidity and mortality, when compared with HIC.31 32 Kitano et al reported on the differential impact of paediatric COVID-19 between HICs and low-income and middle-income countries (LMICs) in a systematic review.33 The paediatric deaths and case fatality rate was significantly higher in LMICs. This is supported by Javalkar et al, who concluded that lower socio-economic status, Hispanic ethnicity and black race were independent risk factors for worse outcomes in children with MIS-C and advocated for targeted interventions to improve health equity for children.34
Strengths and limitations
Follow-up studies of children with MIS-C are limited and our study adds to the growing knowledge base. Our cohort had substantial loss to follow-up, which limits some of our findings. In addition, our cohort did not include children older than 13 years, which is important, as mortality is reported to be higher in older children. Most echocardiograms in this cohort were performed and interpreted by a single operator and not verified and discussed by a few. The preponderance of regurgitation in this cohort could thus be operator-dependent.
Conclusions and recommendations
Our findings are important as it adds to the limited data available on cardiac outcomes in children living in Africa. This is only the second study from Africa looking at the cardiac outcomes of children with MIS-C. Despite low mortality in this cohort, there are some concerns about mid-term cardiac morbidity and the possible implication on long-term cardiovascular health. Further research is needed to inform targeted interventions and ensure adequate long-term follow-up services.
Data availability statement
Data may be obtained from a third party and are not publicly available.
Patient consent for publication
The study was approved under Stellenbosch University Health Research Ethics Committee (HREC number N20/04/013_COVID-019; N20/07/041). The aim of the study was to describe standard practice without any additional intervention. Data were obtained from patient records, the laboratory system and the PACS system. There is minimal risk for breach of patient confidentiality.
Contributors JL: joint first author. Responsible for conceptualisation, project administration and methodology of study. Responsible for data collection. Responsible for data curation and analysis. Had access to data and were responsible for writing the original draft. Responsible for draft review and editing. DRA: joint first author. Responsible for conceptualisation, project administration and methodology of study. Responsible for data collection and rheumatology-immunology follow-up of patients. Had access to data and were responsible for writing the original draft. Responsible for draft review and editing. BF: responsible for data collection and performing echocardiograms and cardiac follow-up of patients. Responsible for draft review and editing. NAY: responsible for data collection and rheumatology-immunology follow-up. Responsible for draft review and editing. AR: responsible for draft review and editing. MMVdZ: responsible for data curation and analysis. Responsible for draft review and editing. HR: responsible for conceptualisation, project administration and methodology of study. Had access to data and were responsible for writing the original draft. Responsible for draft review and editing. JL is guarantor.
Funding DRA and MMVDZ are supported by the South African Medical Research Council (SAMRC) with researcher initiated grants. MMVDZ is supported by a career development grant from the EDCTP2 program supported by the European Union (TMA2019SFP-2836 TB lung-FACT2), the Fogarty International Center of the National Institutes of Health (NIH) under Award Number K43TW011028. Stellenbosch University supplied SEED funding for the start of the project.
Disclaimer The content and findings reported/illustrated are the sole deduction, view and responsibility of the researcher and do not reflect the official position and sentiments of the SAMRC, NIH or National Treasury.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.